227,598 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Purchased by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. has invested approximately $3.27 million in Centessa Pharmaceuticals, acquiring 227,598 shares, representing 0.17% of the company.
• Centessa Pharmaceuticals' stock is currently down by 3.0%, with a market capitalization of $2.28 billion and a PE ratio of -9.50.
• Despite recent insider selling, analysts remain optimistic, with many recommending a "buy" rating and a consensus price target of $28.10.

Russell Investments Group Ltd. purchased a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 227,598 shares of the company's stock, valued at approximately $3,273,000. Russell Investments Group Ltd. owned approximately 0.17% of Centessa Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD boosted its holdings in Centessa Pharmaceuticals by 14.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock valued at $89,854,000 after purchasing an additional 685,371 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock worth $82,218,000 after acquiring an additional 3,614,623 shares during the period. Farallon Capital Management LLC raised its position in shares of Centessa Pharmaceuticals by 24.3% in the fourth quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company's stock worth $58,603,000 after acquiring an additional 684,391 shares during the period. Point72 Asset Management L.P. raised its position in shares of Centessa Pharmaceuticals by 26.2% during the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock worth $57,396,000 after purchasing an additional 710,936 shares during the last quarter. Finally, Foresite Capital Management VI LLC acquired a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth about $20,994,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on CNTA shares. Chardan Capital reiterated a "buy" rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Wall Street Zen cut shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Needham & Company LLC started coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They set a "buy" rating and a $35.00 price objective for the company. Truist Financial assumed coverage on shares of Centessa Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $30.00 price target for the company. Finally, Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a research report on Friday. They set an "outperform" rating and a $40.00 price objective for the company. Eleven research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $31.50.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA traded up $0.23 during trading on Friday, reaching $16.79. The company's stock had a trading volume of 632,847 shares, compared to its average volume of 1,036,740. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of -9.38 and a beta of 1.48. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $9.60 and a twelve month high of $19.09. The business's fifty day moving average price is $15.70 and its 200-day moving average price is $14.49.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). As a group, analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Insider Activity

In other news, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $15.92, for a total value of $875,600.00. Following the sale, the chief executive officer owned 221,017 shares of the company's stock, valued at $3,518,590.64. The trade was a 19.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $15.56, for a total transaction of $155,600.00. Following the completion of the sale, the insider directly owned 122,279 shares in the company, valued at approximately $1,902,661.24. The trade was a 7.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold 171,322 shares of company stock worth $2,472,814 in the last ninety days. 7.09% of the stock is currently owned by insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.